Entresto extends life by roughly 1 to 1.5 years on average for people with heart failure and reduced pumping ability, compared to older standard treatments. In the landmark clinical trial that led to its approval, a modeling analysis published in JACC: Heart Failure estimated that a 60-year-old patient starting Entresto could expect to live about 12.4 years, compared to 11.2 years on the older drug enalapril, a difference of approximately 1.1 years. That number represents a population average, and individual results vary depending on age, dose tolerance, and how advanced the heart failure is.
What the Major Trial Found
The evidence behind Entresto’s survival benefit comes primarily from the PARADIGM-HF trial, which enrolled over 8,000 patients with heart failure and reduced ejection fraction (meaning the heart pumps out less blood than normal with each beat). Compared to enalapril, a well-established heart failure drug, Entresto reduced the risk of dying from cardiovascular causes or being hospitalized for heart failure by 20%. It reduced the risk of dying from any cause by 16%.
The trial was actually stopped early, about 27 months in, because the benefit was so clear that it was considered unethical to keep patients on the less effective treatment. At that point, 21.8% of patients on Entresto had experienced a cardiovascular death or heart failure hospitalization, compared to 26.5% on enalapril. That gap would likely have widened further had the trial continued its full planned duration.
Entresto also cut the risk of sudden cardiac death, the type of fatal heart rhythm disturbance that accounts for a large share of heart failure deaths. In patients with an implantable defibrillator, the risk was cut roughly in half. In those without a defibrillator, it dropped by about 19%.
How Entresto Works Differently
Entresto combines two active components that work on different systems simultaneously. One blocks the hormone system that constricts blood vessels and promotes fluid retention, which is what older heart failure drugs already do. The other prevents the breakdown of natural proteins your body produces to lower blood pressure and reduce strain on the heart. Neither approach works well alone. Blocking the enzyme that breaks down those protective proteins also blocks the breakdown of harmful ones, which cancels out the benefit. By pairing both mechanisms, Entresto tips the balance toward heart protection.
Beyond those two primary effects, the drug appears to slow the physical remodeling of the heart itself. It interferes with processes that cause scarring of heart tissue, thickening of heart walls, and cell death in the heart muscle. This is likely why the benefit grows over time rather than appearing all at once.
Dose Matters More Than You Might Think
Entresto is typically started at a low dose and gradually increased to a target dose. How high you’re able to go has a meaningful impact on outcomes. In one study tracking real-world patients across three dose levels, all-cause mortality was 29.6% in the lowest-dose group, 17.6% in the middle-dose group, and 9.3% in the highest-dose group. Hospitalization rates followed a similar pattern.
The encouraging finding is that you don’t necessarily need to reach the maximum dose to see strong results. The middle dose performed nearly as well as the highest dose on both mortality and hospitalization, with no statistically significant difference between the two. The real drop-off happens at the lowest dose. So if side effects like low blood pressure or dizziness prevent you from reaching the top dose, getting to at least the middle dose still provides substantial protection.
Age and the Benefit Window
Real-world registry data from nearly 2,000 patients in Taiwan confirms that Entresto improves outcomes across age groups, though the size of the benefit shifts with age. Patients under 65 who tolerated at least half the target dose saw all-cause mortality drop by 70% and heart failure hospitalizations drop by 59% compared to those who didn’t reach that threshold. Patients aged 65 to 74 saw similar reductions in hospitalizations and overall outcomes. For patients 75 and older, the benefits were still present but more modest, with about a 40% reduction in the combined outcome of death and hospitalization.
Younger patients appear to benefit from aggressive dose increases, while older patients may benefit more from simply staying on the drug long-term at whatever dose they can tolerate comfortably. This reflects the practical reality that older patients are more likely to experience side effects like low blood pressure or kidney changes that limit dosing.
Who Benefits Most
Entresto’s strongest evidence is in heart failure with reduced ejection fraction, where the heart’s pumping function is measurably weakened. This is the population where the 16% to 20% reductions in death and hospitalization were proven. Current guidelines from the American College of Cardiology give Entresto their highest recommendation (Class I) for these patients.
For heart failure with preserved ejection fraction, where the heart pumps normally but fills poorly, the picture is less clear. A large trial called PARAGON-HF narrowly missed its primary goal, showing a trend toward benefit that didn’t reach statistical significance. However, patients whose ejection fraction was below the study’s midpoint of 57% did see a meaningful reduction in events. Women in the trial also responded significantly better than men, with a 27% reduction in cardiovascular death or hospitalization compared to no benefit in men. This suggests a subset of preserved-ejection-fraction patients may still benefit, and the FDA subsequently expanded Entresto’s indication to include some of these patients.
Putting the Numbers in Perspective
An extra year of life is a meaningful gain for a disease as serious as heart failure, where five-year survival rates have historically hovered around 50%. But these numbers come from comparisons against enalapril, which was already an effective drug. Entresto isn’t being compared to no treatment. The 1.1-year average gain represents the additional benefit over and above what a good standard therapy already provides.
The survival benefit also doesn’t capture the full picture. Fewer hospitalizations means fewer weeks spent in the hospital, less physical decline from each episode, and more time feeling functional at home. In the PIONEER-HF trial, patients started on Entresto during a hospitalization for worsening heart failure had a combined rate of rehospitalization or cardiovascular death of 9.2% over eight weeks, compared to 15.2% for those on enalapril. That early separation suggests the drug starts working quickly, not just over years.
How long Entresto extends any individual life depends on when it’s started, what dose is tolerated, and what other treatments are in place alongside it. The strongest gains go to people who start it relatively early in their disease course, reach at least a moderate dose, and stay on it consistently.